Pioneering sustained back pain treatment

About SpineThera

SpineThera is a clinical-stage company working to improve the lives of patients suffering from radicular leg pain (sciatica). SpineThera’s lead asset, SX600, uses the Faros™ technology to provide months-long sustained-release of dexamethasone from a single epidural injection.

About SpineThera

SpineThera is a clinical-stage company working to improve the lives of patients
suffering from radicular leg pain (sciatica). SpineThera’s lead asset, SX600, uses the
Faros™ technology to provide months-long sustained-release of dexamethasone from a single epidural injection.

Challenge in Back Pain

Back pain, including lumbar radicular pain, is the most common cause of disability within the United States and globally, and is the most expensive indication in healthcare. Currently there is no FDA-approved drug for epidural injection to treat lumbar radicular pain (sciatica).

This debilitating condition commonly requires repeated epidural corticosteroid injections to achieve and maintain adequate pain relief.

Solution

The company’s lead asset, SX600, is a novel formulation of Dexamethasone using Faros™ technology being developed for lumbar radicular pain (sciatica). Clinically meaningful and durable reduction in lumbar radicular pain from a single epidural injection of SX600 in a Phase 2 trial highlighted the potential for best-in-class efficacy.

Phase 2 Clinical Trial

Challenge in Back Pain

Back pain, including lumbar radicular pain, is the most common cause of disability within the United States and globally, and is the most expensive indication in healthcare. Currently, there is no FDA-approved drug for epidural injection to treat lumbar radicular pain (sciatica). This debilitating condition commonly requires repeated epidural corticosteroid injections to achieve and maintain adequate pain relief.

Solution

The company’s lead asset, SX600, is a novel formulation of dexamethasone using Faros™ technology being developed for lumbar radicular pain (sciatica). Clinically meaningful and durable reduction in lumbar radicular pain from a single epidural injection of SX600 in a Phase 2 trial highlighted the potential for best-in-class efficacy.

Phase 2 Clinical Trial